1 / 71

Multidrug-resistant Organisms in Health Care Settings

Multidrug-resistant Organisms in Health Care Settings. Sherman J. Alter, M.D. Division of Infectious Disease The Children’s Medical Center of Dayton Department of Pediatrics Boonshoft School of Medicine Wright State University Dayton, OH. H5N1. Measles. SARS. Monkeypox.

kirestin-livingston
Télécharger la présentation

Multidrug-resistant Organisms in Health Care Settings

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Multidrug-resistant Organisms in Health Care Settings Sherman J. Alter, M.D. Division of Infectious Disease The Children’s Medical Center of Dayton Department of Pediatrics Boonshoft School of Medicine Wright State University Dayton, OH

  2. H5N1 Measles SARS Monkeypox NDM- beta lactamase organisms White nose fungus E. coli O104:H4

  3. Impact of multidrug-resistant organisms (MDROs) on the health care system • Infections caused by MDROs are associated with worsened clinical outcomes, including an increased risk of death. • MDRO infections are also associated with significantly increased costs to hospitals, mostly attributable to increased length of stay. • Media, legislative, and regulatory pressures are additional factors compelling hospitals to more effectively control MDROs.

  4. Factors that might increase antimicrobial resistance in hospitals • Greater severity of illness of hospitalized patients • More severely immunocompromised patients • Newer devices and procedures in use • Increased introduction of resistant organisms from the community • Ineffective infection control and isolation practices and compliance • Increased use of antimicrobial prophylaxis • Increased empiric polymicrobial antibiotic therapy • High antibiotic usage per geographic area per unit time Clin Infect Dis 1997; 25:584-99

  5. Risk factors for health care-associated infections and infection with drug-resistant bacteria Risk factors for health care-associated infections • Hospitalization for >2 days in preceding 90 days • Residence in nursing home or long-term care facility • Home infusion therapy, including antibiotics • Long-term dialysis within 30 days • Home wound care • Family member with multidrug-resistant pathogen Risk factors for infection with antibiotic-resistant bacteria • Antimicrobial therapy in preceding 90 days • Current hospitalization for >5 days • High frequency of antibiotic resistance in community or specific hospital unit • Immunosuppression Peleg et al. N Engl J Med 2010;362:1804-13

  6. Rationale for MDRO control Clinical consequences of MDROs Worsened patient morbidity/mortality Economic consequences of MDROs ↑ costs of managing individual patients, opportunity costs, cost of control programs Legislative mandates ↑ number of states require specific surveillance strategies; many promote or mandate public reporting. Pay-for-performance measures Proposals to MRSA in CMS programs linked to ↓ hospital reimbursement Public image and reputation Patient advocacy groups and media focused on MDRO preparedness Medicolegal liability Lawsuits linking MRSA infection with hospital/provider neglect From What Every Health Care Executive Should Know: The Cost of Antibiotic Resistance. Joint Commission Resources, 2009.

  7. Elements of an effective multidrug resistant organism control program • MDRO and infection control risk assessment • MDRO and infection control performance assessment • Antibiotic stewardship • Transmission control • Education From What Every Health Care Executive Should Know: The Cost of Antibiotic Resistance. Joint Commission Resources, 2009.

  8. Preventing antimicrobial resistance in health care settings Prevent Infections 1. Vaccinate 2. Get the catheters out Diagnose and treat infections effectively 3. Target the pathogen 4. Access the experts Use antimicrobials wisely 5. Practice antimicrobial control 6. Use local data 7. Treat infection, not contamination 8. Treat infection, not colonization 9. Know when to say “no” to “vanco” 10. Stop antimicrobial treatment Prevent transmission 11. Isolate the pathogen 12. Break the chain of contagion http://www.cdc.gov/drugresistance/healthcare/ha/12steps_HA.htm

  9. Antimicrobial-Resistant Pathogen Prevent Infection PreventTransmission Infection Antimicrobial Resistance Effective Diagnosis & Treatment Optimize Use Antimicrobial Use Antimicrobial Resistance:Key Prevention Strategies Susceptible Pathogen Pathogen

  10. Mortality associated with carbapenem resistant (CR) vs susceptible (CS) Klebsiellapneumoniae(KP) p<0.001 p<0.001 OR 3.71 (1.97-7.01) OR 4.5 (2.16-9.35) Patel G et al. ICHE 2008;29:1099-1106

  11. Prevent Infection Step 1: Vaccinate Fact:Pre-discharge influenza and pneumococcal vaccination of at-risk hospital patients AND influenza vaccination of healthcare personnel will prevent infections.

  12. Kwong et al CLIN INFECT DIS  2009 49(5):750-756. Respiratory antibiotic prescription rates over the study period, demonstrating year‐to‐year variability, temporal correlation with Ontario influenza viral surveillance data, and increasing influenza vaccination rates, with greater increases in Ontario than in other provinces combined. Respiratory antibiotic prescriptions are expressed as rate per 1000 people on the left vertical axis. Viral surveillance data (gray‐shaded areas) are expressed as the monthly percentage of positive test results on the right vertical axis. Vaccination rates for the household population aged ⩾12 years (gray vertical bars, Ontario; black vertical bars, other provinces combined) are expressed as the percentage of the population vaccinated on the right vertical axis. The horizontal axis represents time. The black vertical line represents the introduction of the universal influenza immunization program (UIIP).

  13. Kwong et al. CLIN INFECT DIS  2009 49(5):750-756. Dose‐response relationship between change in respiratory antibiotic prescriptions and influenza vaccination rate. The vertical axis represents the pre‐/post‐2000 relative rates for respiratory antibiotic prescriptions. The horizontal axis represents the absolute change in influenza vaccination rate for the household population aged ⩾12 years from 1996–1997 to the mean during the post‐2000 period. Bubble size represents the inverse of the variance of the estimate of relative rate, used as the weighting factor in the weighted linear regression analysis. The solid line represents the weighted linear regression line, and the P value is for the regression coefficient. BC, British Columbia.

  14. Dayton Daily News 09/01/2011

  15. CDC. MMWR. February 15, 2008 / 57(06);144-148

  16. Prevent Infection Step 2: Get the catheters out Fact: Catheters and other invasive devices are the # 1 exogenous cause of hospital-onset infections.

  17. Biofilm on Intravenous Catheter Connecter 24 hours after Insertion Scanning Electron Micrograph

  18. Process of Catheter Related Infections From the Quality and Safety Research Group Johns Hopkins University 2009

  19. Risk Factors for catheter-relatedbloodstream infection • Multiple lumen catheters- • increased tissue trauma predisposes to potential infection • more manipulation and contamination of multiple ports/hubs • Total parenteral nutrition and/or lipid infusions • Low nurse to patient ratio • Site of insertion; subclavian vein poses less risk than internal jugular or femoral vein Merrer et al. JAMA. 2001;286:700-7

  20. Evidence based steps to preventing catheter-related bloodstream infections • Clean hands (waterless alcohol based hand sanitizer or wash hands with soap and water)! • Select best insertion site • Use proper skin preparation (chlorhexidine) • Use maximal barrier precautions • Remove catheter as soon as possible

  21. Diagnose & Treat Infection Effectively Step 3: Target the pathogen Fact:Appropriate antimicrobial therapy (correct regimen, timing, dosage, route, and duration) saves lives.

  22. Diagnose & Treat Infection EffectivelyStep 3:Target the pathogen Fact:Appropriate antimicrobial therapy saves lives. Actions: • culture the patient • target empiric therapy to likely pathogens and local antibiogram • target definitive therapy to known pathogens and antimicrobial susceptibility test results MDROs = microorganisms, predominantly bacteria, that are resistant to one or more classes of antibiotics. These pathogens are frequently resistant to most available antimicrobial agents

  23. Organisms that can effectively “escape” the effects of antibacterial drugs Enterobacter Staphylococcus aureus Klebsiella Acinetobacter Pseudomonas aeruginosa Enterococcus IDSA. Clin Infect Dis 2009;48 (1 January)

  24. Causative agents with 3-class and 4-class antimicrobial resistance within infection types (National Healthcare Safety Network, 2006-2007) Kallenet al. Infect Control Hosp Epidemiol 2010;31:528–531

  25. Giske et al. Antimicrobial Agents and Chemotherapy 2008; 52(3): 813-21.

  26. Use Antimicrobials Wisely Step 5: Practice antimicrobial control Fact:Programs to improve antimicrobial use are effective – antibiotic stewardship

  27. Associations between antimicrobial use and the emergence of antimicrobial resistance • Changes in antimicrobial use are paralleled by changes in the prevalence of resistance. • Antimicrobial resistance is more prevalent in healthcare-associated bacterial infections, compared with those acquired in the community. • Patients with healthcare-associated infections caused by resistant strains are more likely than control patients to have received prior antibiotics. • Areas within hospitals that have the highest rates of antimicrobial resistance also have the highest rates of antimicrobial use. • Increasing duration of patient exposure to antimicrobials increases the likelihood of colonization with resistant organisms. IDSA and SHEA Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship ClinInfect Dis 2007; 44:159-77

  28. Annual prevalence of imipenem resistance in P. aeruginosa vs. carbapenem use rate Gould et al. ICHE 2006;27:923-5

  29. Mechanisms for the appearance or spread of antimicrobial resistance in hospital organisms • Introduction of a resistant organism to a susceptible population • Acquisition of resistance by a susceptible strain • Spontaneous mutation • Genetic transfer • Expression of a regulated resistance already present in the population • Selection of a resistant subpopulation • Dissemination or spread of resistant organisms Clin Infect Dis 1997; 25:584-99

  30. Infectious Disease Society of America (IDSA) Society for Healthcare Epidemiology of America (SHEA) CID 2007:44 159-177

  31. Antibiotic stewardship: methods to control antimicrobial use to prevent or control antimicrobial resistance • Optimal use of all antimicrobials (e.g., incorporate practice guidelines) • Selective removal, control, or restriction of antimicrobial agents or classes • Rotational or cyclic antimicrobial utilization • Use of combination antimicrobial therapy to prevent the emergence of resistance • Formulary restriction • Intravenous to oral switch • Automatic stop orders • Computerized order entry • Provider education (best when used • with other interventions)

  32. Ten Strategies proposed by IDSA and SHEA for implementation of an Antibiotic Stewardship (AS) Program 1. Prospective audit with intervention and feedback (A-I) 2. Formulary restriction and pre-authorization (A-II) 3. Education with intervention (A-III) 4. Guidelines with clinical pathways (A-III) 5. Antimicrobial cycling (C-II) 6. Antimicrobial order forms (B-II) 7. Reducing combination therapy (C-II) 8. Streamlining and de-escalation therapy (A-II) 9. Dose optimization (A-II) 10. Parenteral or oral conversion (A-III)

  33. Carbapenem-resistant Pseudomonas aeruginosaand carbapenem utilization Lepper et al. AAC 2002;46:2920-5

  34. Winter antibiotic prescriptions, France by region, October 2000 to March 2007 From 2001 to 2006, a decreasing trend was observed in the rate of pneumococci resistant to penicillin (47% to 32% of isolates) and the rate of pneumococci resistant to macrolides (49% to 36%) Sabuncu et al. PLoS Med. 2009 June; 6(6): e1000084 (Epub)

  35. Use Antimicrobials Wisely Step 6: Use local data Fact: The prevalence of resistance can vary by time, locale, patient population, hospital unit, and length of stay.

  36. Methicillin -resistant Staphylococcus aureusDCMC Percent Resistant

  37. Surveillance as a strategy to prevent the spread of MDROs Active surveillance to identify patients colonized but not overtly infected with MDROs • Specimens from body sites can be submitted for culture • By identifying these individuals, measures can be taken to prevent the spread to other patients. • Active surveillance has been shown to reduce the frequency of MDRO infection in specific populations in a wide variety of settings.

  38. CDC. MMWR 2009;58:256-258

  39. Use Antimicrobials Wisely Step 7: Treat infection,notcontamination Fact:A major cause of antimicrobial overuse is “treatment” of contaminated cultures.

  40. Mean blood culture contamination rate 1.9%. For ~600 children per quarter who had a blood draw from the lab personnel, 12 had a contaminated blood culture. DCMC Microbiology Laboratory

  41. Mean blood culture contamination rate decreased from 3.3% to 1.4% 2001-2009. The number of children with a contaminated blood culture was reduced from 236 to 103 (7130 blood cultures per year total). That’s 133 children spared repeat visits, admissions, prolonged stays, excess charges and potential hospital acquired infections by undergoing further evaluations or being admitted unnecessarily. DCMC Microbiology Laboratory

  42. Use Antimicrobials Wisely Step 9: Know when to say “no” to vancomycin Fact:Vancomycin overuse promotes emergence, selection, and spread of resistant pathogens.

  43. Methicillin Methicillin-resistant S. aureus (MRSA) [1970s] Vancomycin [1997] [1990s] [ 2002 ] Vancomycin Vancomycin-resistant Vancomycin- resistant S. aureus intermediate- enterococci (VRE) resistant S. aureus (VISA) Evolution of Drug Resistance in S. aureus Penicillin Penicillin-resistant S. aureus [1950s] S. aureus

  44. “Colonization pressure” in the spread of vancomycin-resistant enterococcus Bonten, M. J. M. et al. Arch Intern Med 1998;158:1127-1132.

More Related